In the last three months, 8 analysts have published ratings on Gilead Sciences GILD, offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 5 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $79.5, along with a high estimate of $105.00 and a low estimate of $69.00. A decline of 5.03% from the prior average price target is evident in the current average.
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Gilead Sciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $74.00 | $74.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $76.00 | $80.00 |
| Tyler Van Buren | TD Cowen | Lowers | Buy | $85.00 | $90.00 |
| Matthew Harrison | Morgan Stanley | Lowers | Equal-Weight | $78.00 | $80.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $74.00 | $76.00 |
| Morten Herholdt | HSBC | Announces | Hold | $69.00 | - |
| Hartaj Singh | Oppenheimer | Maintains | Outperform | $105.00 | $105.00 |
| Colin Bristow | UBS | Lowers | Neutral | $75.00 | $81.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Gilead Sciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Gilead Sciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Gilead Sciences analyst ratings.
Delving into Gilead Sciences's Background
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Gilead Sciences: A Financial Overview
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Gilead Sciences's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 5.26%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Gilead Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -62.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -20.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Gilead Sciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.04%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.44.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
